Shots:
- The EC has approved Eyluxvi (ALT-L9), a biosimilar version of Eylea (aflibercept), to treat wet AMD, visual impairment due to macular oedema secondary to branch/central retinal vein occlusion & visual impairment due to diabetic macular oedema & myopic choroidal neovascularisation
- Approval was based on P-III trials conducted across the EU, South Korea, & Japan, incl. a trial assessing Eyluxvi vs Eylea in 431 wet AMD pts, which showed similar efficacy & safety between the two
- Eyluxvi is a fusion protein that blocks VEGF-A & PIGF from binding to VEGFR-1/2 to reduce neovascularization & vascular permeability, thereby slowing vision loss in retinal diseases
Ref: PRNewsWire | Image: Alteogen | Press Release
Related News:- Alteogen’s Eyluxvi (Biosimilar, Eylea) Receives the CHMP’s Positive Opinion for Retinal Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
